This is a preview of subscription content, log in via an institution to check access.
Notes
The analysis and the parent study were funded by GlaxoSmithKline.
Reference
Yang S, et al. Healthcare Resource use in Patients with Severe Eosinophilic Asthma after the Initiation of Mepolizumab in Real-Life Settings: REALITI-A Study. 25th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research : (plus poster) abstr. N/A, 18 May 2020. Available from: URL: https://www.ispor.org/heor-resources/presentations-database/presentation/intl2020-3182/101382
Rights and permissions
About this article
Cite this article
Mepolizumab in severe eosinophilic asthma reduces healthcare use. PharmacoEcon Outcomes News 855, 22 (2020). https://doi.org/10.1007/s40274-020-6887-1
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-020-6887-1